Evidence map›Paper›PMID 41168121›Full record

GuidelineEuropean journal of heart failure2025

European Journal of Heart Failure expert consensus statement on transcatheter treatment of mitral regurgitation in heart failure.

Christos Iliadis, Marianna Adamo, Volker Rudolph, Nicole Karam, Ralph Stephan von Bardeleben, Stefan D Anker, Victoria Delgado, Jörg Hausleiter, Hannah Kempton, Marco Metra and 2 more

Abstract readConsensus StatementPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in European journal of heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Christos IliadisDepartment of Internal Medicine III, Faculty of Medicine and University Hospital Cologne, University of Cologne, and Center for Cardiovascular Medicine (CCMABCD), partner site Cologne, Cologne, Germany.
Marianna AdamoCardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Volker RudolphGeneral and Interventional Cardiology, Heart and Diabetes Centre NRW, University Hospital of the Ruhr-University Bochum, Medical Faculty OWL, Bad Oeynhausen, Germany.
Nicole KaramDepartment of Cardiology, European Hospital Georges Pompidou and Paris Cardiovascular Research Centre (INSERM U970), Paris, France.
Ralph Stephan von BardelebenDepartment of Cardiology, University Medical Centre Mainz, Mainz, Germany.
Stefan D AnkerDepartment of Cardiology (CVK) of German Heart Centre Charité; German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universitätsmedizin, Berlin, Germany.
Victoria DelgadoCardiovascular Imaging Section, Department of Cardiology, Heart Institute, University Hospital Germans Trias i Pujol, Badalona, Spain.
Jörg HausleiterMedizinische Klinik und Poliklinik I, LMU-Klinikum, LMU München, Munich, Germany.
Hannah KemptonMedizinische Klinik und Poliklinik I, LMU-Klinikum, LMU München, Munich, Germany.
Marco MetraCardiology, ASST Spedali Civili, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy.
Michael BöhmDepartment of Cardiology, Angiology and Internal Intensive Care, University Hospital of Saarland, Saarland University, Homburg, Germany.
Stephan BaldusDepartment of Internal Medicine III, Faculty of Medicine and University Hospital Cologne, University of Cologne, and Center for Cardiovascular Medicine (CCMABCD), partner site Cologne, Cologne, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary mitral regurgitation (SMR) is highly prevalent in patients with heart failure (HF), associated with poor prognosis, and its treatment is typically preceded by implementing pharmacotherapy for HF as well as cardiac resynchronization therapy. Given the increase in experience and important technological iterations, transcatheter mitral valve repair has witnessed increasing safety and efficacy. Recently, two randomized controlled trials extended the level of evidence for this intervention in patients with SMR: RESHAPE-HF2 randomized patients with less severe SMR to either medical therapy alone versus adjunct transcatheter repair, whereas the MATTERHORN trial compared surgical therapy with transcatheter mitral valve repair in patients with SMR and increased risk for surgery. These two trials have a potential impact on the indications of transcatheter repair. Here we discuss updated indications for transcatheter mitral valve therapy across the different subtypes of SMR, revisit the current body of evidence for transcatheter mitral valve repair and classify this technique into the current treatment hierarchy of SMR in patients with HF.

Indexed as

Cardiac CatheterizationHeart FailureHeart Valve Prosthesis ImplantationMitral ValveMitral Valve InsufficiencyEuropeHumansConsensus statementHeart failureMitral valveSecondary mitral regurgitationTranscatheter edge‐to‐edge repair

Identifiers

PMID41168121
PMCPMC12765465

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.